PL3336197T3 - Markery epigenetyczne oraz powiązane sposoby i środki wykrywania i leczenia raka jajnika - Google Patents

Markery epigenetyczne oraz powiązane sposoby i środki wykrywania i leczenia raka jajnika

Info

Publication number
PL3336197T3
PL3336197T3 PL16204822.7T PL16204822T PL3336197T3 PL 3336197 T3 PL3336197 T3 PL 3336197T3 PL 16204822 T PL16204822 T PL 16204822T PL 3336197 T3 PL3336197 T3 PL 3336197T3
Authority
PL
Poland
Prior art keywords
management
detection
ovarian cancer
related methods
epigenetic markers
Prior art date
Application number
PL16204822.7T
Other languages
English (en)
Inventor
Martin Widschwendter
Allison JONES
Iona EVANS
Harri LEMPPIÄINEN
Johannes EICHNER
Tamas Rujan
Timo Wittenberger
Tobias PAPROTKA
Benjamin WAHL
Original Assignee
Eurofins Genomics Europe Sequencing GmbH
Genedata AG
Ucl Business Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eurofins Genomics Europe Sequencing GmbH, Genedata AG, Ucl Business Ltd filed Critical Eurofins Genomics Europe Sequencing GmbH
Publication of PL3336197T3 publication Critical patent/PL3336197T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/10Signal processing, e.g. from mass spectrometry [MS] or from PCR
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/112Disease subtyping, staging or classification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/118Prognosis of disease development
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/154Methylation markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medical Informatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Theoretical Computer Science (AREA)
  • Databases & Information Systems (AREA)
  • Primary Health Care (AREA)
  • Data Mining & Analysis (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Signal Processing (AREA)
  • Artificial Intelligence (AREA)
  • Bioethics (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Evolutionary Computation (AREA)
  • Software Systems (AREA)
PL16204822.7T 2016-12-16 2016-12-16 Markery epigenetyczne oraz powiązane sposoby i środki wykrywania i leczenia raka jajnika PL3336197T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16204822.7A EP3336197B1 (en) 2016-12-16 2016-12-16 Epigenetic markers and related methods and means for the detection and management of ovarian cancer

Publications (1)

Publication Number Publication Date
PL3336197T3 true PL3336197T3 (pl) 2022-08-08

Family

ID=57609702

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16204822.7T PL3336197T3 (pl) 2016-12-16 2016-12-16 Markery epigenetyczne oraz powiązane sposoby i środki wykrywania i leczenia raka jajnika

Country Status (9)

Country Link
US (3) US11920200B2 (pl)
EP (3) EP3336197B1 (pl)
AU (2) AU2017375038A1 (pl)
CA (2) CA3047202A1 (pl)
DK (1) DK3336197T3 (pl)
HU (1) HUE059194T2 (pl)
IL (2) IL267302A (pl)
PL (1) PL3336197T3 (pl)
WO (2) WO2018109217A1 (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12027237B2 (en) 2018-03-13 2024-07-02 Grail, Llc Anomalous fragment detection and classification
EP3814500A4 (en) * 2018-06-27 2022-03-16 The Trustees of Indiana University METHODS FOR URINE DNA ANALYSIS
AU2019362972A1 (en) * 2018-10-17 2021-05-20 The University Of Queensland Epigenetic biomarker and uses therefor
AU2020337349A1 (en) * 2019-08-23 2022-03-10 Agex Therapeutics, Inc. Differentially-methylated regions of the genome useful as markers of embryo-adult transitions
CA3154235A1 (en) * 2019-09-13 2021-03-18 University Health Network Detection of circulating tumor dna using double stranded hybrid capture
CN112921085B (zh) * 2019-12-06 2022-06-10 广州医科大学附属第三医院(广州重症孕产妇救治中心、广州柔济医院) Circ-NOLC1作为卵巢癌诊断标志物及其应用
CN112921086B (zh) * 2019-12-06 2022-12-02 广州医科大学附属第三医院(广州重症孕产妇救治中心、广州柔济医院) Circ-CRIM1作为卵巢癌诊断标志物及其应用
EP4081655A1 (en) 2019-12-24 2022-11-02 Vib Vzw Disease detection in liquid biopsies
EP4284951A1 (en) * 2021-01-29 2023-12-06 Mayo Foundation for Medical Education and Research Detecting the presence or absence of multiple types of cancer
CA3208638A1 (en) * 2021-02-17 2022-08-25 Budur SALHIA Cell-free dna methylation test
EP4170661A1 (en) * 2021-10-19 2023-04-26 Institut National de la Santé et de la Recherche Médicale (INSERM) Methylation profile analysis using smoothing method

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6582908B2 (en) 1990-12-06 2003-06-24 Affymetrix, Inc. Oligonucleotides
US6017704A (en) 1996-06-03 2000-01-25 The Johns Hopkins University School Of Medicine Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids
US5786146A (en) 1996-06-03 1998-07-28 The Johns Hopkins University School Of Medicine Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids
US6331393B1 (en) 1999-05-14 2001-12-18 University Of Southern California Process for high-throughput DNA methylation analysis
US20050064401A1 (en) 2000-09-01 2005-03-24 Alexander Olek Diagnosis of illnesses or predisposition to certain illnesses
US20040234960A1 (en) 2000-09-01 2004-11-25 Alexander Olek Method for determining the degree of methylation of defined cytosines in genomic dna in the sequence context 5'-cpg-3'
WO2007019670A1 (en) 2005-07-01 2007-02-22 Graham, Robert Method and nucleic acids for the improved treatment of breast cancers
EP1862555A1 (en) 2006-05-29 2007-12-05 Klinikum der Universität Regensburg Means and methods for diagnosing cancer or a corresponding predisposition
WO2009153667A2 (en) * 2008-06-17 2009-12-23 Occure Gmbh Method for the detection of ovarian cancer
GB201102014D0 (en) 2011-02-04 2011-03-23 Ucl Business Plc Method for predicting risk of developing cancer
US20140094380A1 (en) 2011-04-04 2014-04-03 The Board Of Trustees Of The Leland Stanford Junior University Methylation Biomarkers for Diagnosis of Prostate Cancer
EP2514836B1 (en) 2011-04-19 2016-06-29 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Prostate cancer markers
US20130041047A1 (en) 2011-06-01 2013-02-14 Aros Applied Biotechnology As Urinary Methylation Markers for Bladder Cancer
US8885324B2 (en) 2011-07-08 2014-11-11 Kemet Electronics Corporation Overvoltage protection component
US20130129668A1 (en) * 2011-09-01 2013-05-23 The Regents Of The University Of California Diagnosis and treatment of arthritis using epigenetics
CA2938451C (en) * 2014-01-30 2023-10-17 The Regents Of The University Of California Methylation haplotyping for non-invasive diagnosis (monod)
WO2016109712A1 (en) * 2014-12-31 2016-07-07 Case Western Reserve University Methods and compositions for detecting esophageal neoplasias and/or metaplasias in the esophagus
US10961590B2 (en) * 2015-09-17 2021-03-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cancer detection methods

Also Published As

Publication number Publication date
WO2018109217A1 (en) 2018-06-21
HUE059194T2 (hu) 2022-10-28
EP3555309A1 (en) 2019-10-23
US11920200B2 (en) 2024-03-05
EP3555308B1 (en) 2023-12-13
AU2017375038A1 (en) 2019-07-04
AU2017378196A1 (en) 2019-07-04
EP3555308A1 (en) 2019-10-23
EP3555309B1 (en) 2023-09-13
DK3336197T3 (da) 2022-07-11
US20190323090A1 (en) 2019-10-24
EP3336197B1 (en) 2022-04-06
US20190330703A1 (en) 2019-10-31
IL267300A (en) 2019-08-29
CA3047208A1 (en) 2018-06-21
EP3336197A1 (en) 2018-06-20
IL267302A (en) 2019-08-29
CA3047202A1 (en) 2018-06-21
US20240200142A1 (en) 2024-06-20
EP3555309C0 (en) 2023-09-13
EP3555308C0 (en) 2023-12-13
WO2018109212A1 (en) 2018-06-21

Similar Documents

Publication Publication Date Title
IL267300A (en) Epigenetic markers and methods and measures related to them for the detection and management of ovarian cancer
EP3535415A4 (en) TUMOR DETECTION METHODS AND SYSTEMS
HK1246828A1 (zh) 用於檢測癌症的生物標志物組
EP3159398A4 (en) Liver cancer detection kit or device, and detection method
PL3357000T3 (pl) Systemy i metody wykrywania raka
EP3156483A4 (en) Prostate cancer detection kit or device, and detection method
IL253160B (en) Cancer markers and methods of using them
IL253710A0 (en) Biomarkers for pancreatic cancer, and kits and methods to detect them
SG11201608347QA (en) Markers for ovarian cancer and the uses thereof
HK1257686A1 (zh) 用於匹配腫瘤學特徵的系統和方法
EP3544605A4 (en) METHOD OF DETECTING CANCER
EP3457116A4 (en) TUMOR CELL DETECTION PROCEDURE AND TUMOR CELL DETECTION DEVICE
IL254119A0 (en) Blood-based mrna markers for prostate cancer prediction and methods for its detection
EP3271483A4 (en) Methods and materials for assessing and treating cancer
GB201602210D0 (en) Detection of cancer
NO20160882A1 (en) Hydrocarbon detection
EP3182132A4 (en) Cancer evaluation method and cancer evaluation system
GB201718352D0 (en) Devices and methods for detection of biomarkers
EP3468564A4 (en) METHOD FOR DIAGNOSTICING AND TREATING METASTASIVE CANCER
EP3184635A4 (en) Cancer marker and cancer determination method
HK1215285A1 (zh) 用於檢測腸癌的標記物及其應用
EP3183366A4 (en) Systems and methods of detecting solid tumor cancer
HK1246851A1 (zh) 檢測癌症的方法
SG10201705455PA (en) Systems and methods for flash detection
SG10202103525UA (en) Cancer biomarkers and methods of use